dc.contributor.author | Huddart, RA | |
dc.contributor.author | Siefker-Radtke, AO | |
dc.contributor.author | Balar, AV | |
dc.contributor.author | Bilen, MA | |
dc.contributor.author | Powles, T | |
dc.contributor.author | Bamias, A | |
dc.contributor.author | Castellano, D | |
dc.contributor.author | Khalil, MF | |
dc.contributor.author | Van Der Heijden, MS | |
dc.contributor.author | Koshkin, VS | |
dc.contributor.author | Pook, DW | |
dc.contributor.author | Özgüroğlu, M | |
dc.contributor.author | Santiago, L | |
dc.contributor.author | Zhong, B | |
dc.contributor.author | Chien, D | |
dc.contributor.author | Lin, W | |
dc.contributor.author | Tagliaferri, MA | |
dc.contributor.author | Loriot, Y | |
dc.date.accessioned | 2020-10-12T11:35:06Z | |
dc.date.issued | 2020-09-16 | |
dc.identifier.citation | Future oncology (London, England), 2020 | |
dc.identifier.issn | 1479-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4140 | |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.doi | 10.2217/fon-2020-0795 | |
dc.description.abstract | The choice of first-line therapy for patients with metastatic urothelial cancer (mUC) is based on cisplatin-eligibility and programmed death-ligand 1 (PD-L1) status. For patients with mUC who are ineligible for cisplatin and with low PD-L1 expression, chemotherapy-based regimens are the only approved first-line option. In a Phase I/II trial of the chemotherapy-free regimen, bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab, patients with locally advanced or mUC experienced tumor responses regardless of baseline PD-L1 expression (objective response rates: 50 and 45% in patients with PD-L1-positive and -negative tumors, respectively). The Phase II PIVOT-10 study (NCT03785925), evaluates efficacy and safety of first-line BEMPEG plus nivolumab in cisplatin-ineligible patients with locally advanced or mUC. Most patients will have low PD-L1 expression. Primary end point: objective response rates (including complete response). | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FUTURE MEDICINE LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.2217/fon-2020-0795 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-09-17 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Future oncology (London, England) | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.publication-status | Published | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Academic Radiotherapy (Huddart) | |
dc.contributor.icrauthor | Huddart, Robert | |